Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US5530178

Title:Mutant mouse lacking CD8 surface marker
Inventors:Mak, Tak W.; Toronto, Canada
Summary:This invention introduces a mutant mouse lacking CD8 on the surface of T lymphocytes. Elucidated herein are properties of a mutant mouse strain without CD8 (Lyt-2 and Lyt-3) expression on the cell surface which has been generated by disruption of the Lyt-2 gene and homologous recombination such that CD8+ T lymphocytes are not present in peripheral lymphoid organs, but the CD4+ T lymphocyte population remains unaltered. Claims of the invention include a decreased cytotoxic response of T lymphocytes in such mice against alloantigens and viral antigens, but an unaffected proliferative response against alloantigens and B lymphocytes. Therapeutic and experimental applications of such mice are included for use as models of diseases of the immune system and in drug development.
Abstract:A mutant mouse strain without CD8 (Lyt-2 and Lyt-3) expression on the cell surface has been generated by disrupting the Lyt-2 gene using embryonic stem cell technology. In these mammals, for example, mice, CD8.sup.+ T lymphocytes are not present in peripherial lymphoid organs, but the CD4.sup.+ T lymphocyte population seems to be unaltered. Cytotoxic response of T lymphocytes from these mice against alloantigens and viral antigens is dramatically decreased. Proliferative response against alloantigens and in vivo help to B lymphocytes, however, are not effected. These mice should be useful for drug development and for studies of diseases of the immune system such as, autoimmunity, immunodeficiency, transplant rejection and tumor rejection.
US Patent Website:Click Here for Full Text of Patent
Title Number:US5530178
Application Number:US1993000097930
Date Filed:28/07/1993
Date Published:25/06/1996
Assignee:The Ontario Cancer Institute, Toronto, Canada


 
Copyright © 2007 The Institute for Cellular Medicine  6/18/2021